Getting Biotechs GlobalReady
Start in Australia, then seamlessly move to North America, Asia Pacific, and Europe without changing CROs or data standards. Every product development program is different. GlobalReady is built around yours.
30+ Years of
Deep Clinical
Research
Management
90+ GlobalReady Biotech Clients
A proven model trusted by biotechs across every stage of development.
Extending Budgets by up to 43.5%
Secure the Australian Government R&D rebate on your clinical trial spend.
Up to 5-6 Week Start-Up
Site Initiation Visit and Study Start delivered faster than anywhere else in the world.
Globally Accepted Data
World-class data accepted by the FDA, EMA, TGA, and all major regulatory authorities.
2026 Global Biotechnology CRO Company of the Year
Global Pathways
No matter which regions your program touches, you’ll work with the same scientific and regulatory experts, the same data standards, and one integrated Avance Clinical team. From first-in-human planning through late-phase work, our direct operations and trusted global partner network mean your program can expand into new regions without handoffs or gaps in oversight.
Where Does Your
Program Need To Go?
Every biotech’s journey is different. Below are the regional pathways
available through GlobalReady, and what each one offers your program.
Frequently Asked Questions
Get answers to frequently asked questions about Avance Clinical’s GlobalReady offering.
No. Australia’s Clinical Trial Notification (CTN) scheme means biotechs can begin early-phase studies without an IND, saving up to a year in regulatory processing time and considerable costs. Avance Clinical has extensive experience with both the CTN and CTX schemes and can advise on which pathway fits your program. Learn more about the Australian Advantage →
Avance Clinical’s clients are currently experiencing a 3-week IRB/EC turnaround. From Site Initiation Visit to study start is typically achieved in 5-6 weeks, which is faster than anywhere else in the world.
Yes. Avance Clinical generates ICH-GCP-compliant data accepted by all major regulatory authorities, including the FDA, EMA, TGA, MHRA, MFDS, and PDMA. See how Avance Clinical’s global scientific and regulatory affairs team manages this across regions.
Biotechs conducting trials in Australia can access up to 43.5% back on eligible clinical spend through the Australian Government’s R&D Tax Incentive, a non-dilutive source of funding that can extend across your development timeline.
Yes, that’s the premise of GlobalReady. Biotechs can start early phases in Australia and progress to North America, Asia Pacific, or Europe for later phases without changing CROs, teams, or data standards. With access to Avance Clinical’s trusted Centers of Excellence and multidisciplinary experts available for every program challenge, you walk away with globally accepted data and documentation.
Avance Clinical has direct operations across Australia, New Zealand, and North America, with established operations in South Korea and Taiwan — expanding into Singapore, Malaysia, India, and mainland China. European countries and site/patient recruitment are delivered through our growing team and/or trusted regional partners. View all locations →
GlobalReady supports programs across all major modalities — small molecules, monoclonal antibodies, ADCs, cell-based therapies, viral vector products, and nucleotide-based therapeutics — and across therapeutic areas including Oncology, CNS, Rare Disease, Renal and Metabolic.
Go Global. Start in Australia.
Talk to the Avance Clinical team about building a GlobalReady pathway for your program.